The fact that only a subset of patients responds to available ICIs, mainly targeting PD-1/PD-L1 and CTLA-4 axes, highlights the importance of the other ICPs in mediating tumor cells' immune evasion. The gene discussed is CTLA4; the disease is neoplasm.